Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dominari Holdings Inc. stock logo
DOMH
Dominari
$4.59
-2.8%
$4.64
$0.83
$13.58
$67.22M0.591.23 million shs393,492 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.31
+2.7%
$1.48
$0.77
$6.40
$19.56M0.382.96 million shs59,803 shs
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$0.91
+0.6%
$1.11
$0.55
$3.06
$8.13M1.31.94 million shs112,896 shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
$3.23
$289K1.07778,054 shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dominari Holdings Inc. stock logo
DOMH
Dominari
+0.85%-0.42%-0.84%-39.25%+121.60%
Longeveron Inc. stock logo
LGVN
Longeveron
-4.85%-4.14%-22.73%-16.67%+19.16%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
0.00%-16.97%-14.62%-34.89%-56.59%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%-97.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.9814 of 5 stars
0.02.00.00.03.02.50.6
Longeveron Inc. stock logo
LGVN
Longeveron
3.3984 of 5 stars
3.65.00.00.02.01.71.3
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
2.5874 of 5 stars
3.05.00.00.02.50.01.3
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00
N/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67561.58% Upside
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
2.00
Hold$3.00229.67% Upside
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DOMH, LGVN, POAI, and TFFP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Longeveron Inc. stock logo
LGVN
Longeveron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/3/2025
Longeveron Inc. stock logo
LGVN
Longeveron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dominari Holdings Inc. stock logo
DOMH
Dominari
$24.89M2.70N/AN/A$9.90 per share0.46
Longeveron Inc. stock logo
LGVN
Longeveron
$2.23M8.79N/AN/A$2.68 per share0.49
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$1.73M4.70N/AN/A$2.04 per share0.45
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$70.98K-4.07N/AN/A$4.04 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dominari Holdings Inc. stock logo
DOMH
Dominari
-$22.88M-$4.50N/AN/A-180.22%-32.89%-29.47%8/6/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%N/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
-$13.98M-$3.05N/AN/AN/A-1,012.32%-286.30%-122.11%8/12/2025 (Estimated)
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.44N/AN/A-1,596.64%-310.17%-196.06%N/A

Latest DOMH, LGVN, POAI, and TFFP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 million
4/15/2025Q4 2024
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A$0.20N/A$0.20N/A$6.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A
10.25
10.25
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
7.67
7.67
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/A
1.20
1.06
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/A
0.89
0.89

Institutional Ownership

CompanyInstitutional Ownership
Dominari Holdings Inc. stock logo
DOMH
Dominari
42.48%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
9.04%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
15.25%

Insider Ownership

CompanyInsider Ownership
Dominari Holdings Inc. stock logo
DOMH
Dominari
32.98%
Longeveron Inc. stock logo
LGVN
Longeveron
19.12%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
3.44%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dominari Holdings Inc. stock logo
DOMH
Dominari
414.64 million4.01 millionNot Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million12.00 millionNot Optionable
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
308.93 million6.44 millionNot Optionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionOptionable

Recent News About These Companies

TFF Pharmaceuticals approves dissolution plan
TFF Pharmaceuticals terminates employees, to wind down operations
TFF Pharmaceuticals to Dissolve and Liquidate Assets
TFF Pharmaceuticals Announces It Will Wind Down Operations
Post-COVID Trends in Biopharma Contract Manufacturing
The Yadot Group to Acquire Experiential Agency Socials Dallas

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dominari stock logo

Dominari NASDAQ:DOMH

$4.59 -0.13 (-2.75%)
As of 04:00 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.31 +0.04 (+2.75%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 -0.01 (-0.76%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Predictive Oncology stock logo

Predictive Oncology NASDAQ:POAI

$0.91 +0.01 (+0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 -0.01 (-1.32%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

$0.06 0.00 (0.00%)
As of 04/10/2025

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.